Last reviewed · How we verify
Full dose CBD
At a glance
| Generic name | Full dose CBD |
|---|---|
| Also known as | Active fulldose of Cannabidiol for 11 days during inpatient alcohol cessation |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- High blood pressure
- Dry mouth/throat discomfort
- Stomachache
- Insertion site pain at site of blood draw
- Lassitude
- Decreased appetite
- Palpitations
- Panic attack symptoms
- Feeling "heady"
- Muscle twitching
- Derealization
- Acid reflux
Key clinical trials
- EFFECTS OF A FULL SPECTRUM CANNABIS EXTRACT WITH DIFFERENT DOSES OF CBD AND THC ON THE MODULATION OF FIBROMYALGIA: A PILOT, MULTICENTER, OPEN LABEL CLINICAL TRIAL (FRIDINHA) (PHASE1, PHASE2)
- Sublingual Cannabidiol for Anxiety (PHASE2)
- Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty (PHASE2)
- Cannabidiol and Alcohol Use Disorder Phenotypes (PHASE2)
- Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. (PHASE1, PHASE2)
- Stratification and Treatment in Early Psychosis Study -ASSIST (PHASE3)
- Cannabinoids and Traumatic Brain Injury: A Randomized, Placebo Controlled Trial (PHASE2)
- Reducing Pain and Opioid Use With CBD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Full dose CBD CI brief — competitive landscape report
- Full dose CBD updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI